NASDAQ$ALEC
Alector Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Alector reported its fourth quarter and full year 2024 financial results, showing a significant increase in collaboration revenue and a reduced net loss compared to the previous year.
Alector reported a strong fourth quarter in 2024, with collaboration revenue significantly increasing to $54.2 million from $15.2 million in the same period last year. The company also reduced its net loss to $2.1 million, or $0.02 per share, compared to a net loss of $41.4 million, or $0.49 per share, in Q4 2023. Cash, cash equivalents, and investments totaled $413.4 million, providing a runway through 2026.
- Collaboration revenue for Q4 2024 increased significantly to $54.2 million, up from $15.2 million in Q4 2023.
- Net loss for Q4 2024 was $2.1 million, a substantial improvement from a $41.4 million net loss in Q4 2023.
- Cash, cash equivalents, and investments stood at $413.4 million as of December 31, 2024, providing financial runway through 2026.
- The company anticipates topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN by Q4 2025.
Headline financials
Revenue & EPS history
Alector · Revenue · Quarterly
$54.2M
Revenue by segment
Alector · $9.11M total across 1 segment · Q3 2023
- Collaboration Revenue$9.11M-38.7%100.0%
Forward guidance
For the year ending 2025, Alector anticipates collaboration revenue between $5 million and $15 million, total research and development expenses between $175 million and $185 million, and total general and administrative expenses between $55 million and $65 million.
Tailwinds
- Anticipated topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN by Q4 2025.
- Expected completion of enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 by mid-2025.
- Advancing preclinical and early research pipeline, including ADP037-ABC (anti-amyloid beta) and ADP050-ABC (GCase replacement therapy) towards IND-enabling studies.
- Plans to enter the clinic with ADP037-ABC and ADP050-ABC programs in 2026.
- Financial runway through 2026 with $413.4 million in cash, cash equivalents, and investments.
Headwinds
- The INVOKE-2 Phase 2 clinical trial for AL002 (TREM2 agonist) did not meet its primary endpoint.
- Collaboration revenue guidance for 2025 ($5 million to $15 million) is significantly lower than 2024 actuals ($100.6 million), indicating a potential decrease in collaboration-related income.
- Total research and development expenses are projected to remain high, between $175 million and $185 million for 2025.
- Total general and administrative expenses are projected to remain substantial, between $55 million and $65 million for 2025.
- The company continues to operate at a net loss, although it has decreased.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.1%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-5.5%
Avg return
30 days after
52%
15 / 29 earnings
Positive
+32.9%
Q2 2023
Best reaction
-18.4%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.1% | -16.0% | -36.6% | |
| Q4 2025 | +7.1% | -11.7% | -16.3% | |
| Q3 2025 | +4.1% | +8.4% | -2.8% | |
| Q1 2025 | +4.2% | +7.4% | +23.8% | |
| Q4 2024 | -3.5% | -15.4% | -25.0% | |
| Q3 2024 | +12.8% | +21.3% | -56.8% | |
| Q2 2024 | +0.8% | +0.9% | -4.2% | |
| Q1 2024 | -1.9% | +1.7% | -17.7% | |
| Q4 2023 | +7.9% | +14.4% | -7.1% | |
| Q3 2023 | -2.6% | -17.7% | +6.0% | |
| Q2 2023 | +32.9% | +12.4% | -15.6% | |
| Q1 2023 | +13.0% | +20.6% | +8.5% | |
| Q4 2022 | +0.9% | -9.5% | -30.3% | |
| Q3 2022 | -18.4% | +3.1% | +3.1% | |
| Q2 2022 | +16.3% | +12.7% | -6.9% | |
| Q1 2022 | -12.7% | -20.0% | -11.9% | |
| Q4 2021 | +1.9% | -1.3% | -7.8% | |
| Q3 2021 | +2.3% | +4.1% | -20.7% | |
| Q2 2021 | +9.5% | +9.0% | +10.1% | |
| Q1 2021 | -7.8% | -12.4% | +6.1% | |
| Q4 2020 | -4.7% | -10.7% | -14.3% | |
| Q3 2020 | +0.4% | +7.2% | +25.2% | |
| Q2 2020 | -6.9% | -7.4% | -13.5% | |
| Q1 2020 | -5.0% | +0.3% | +3.7% | |
| Q4 2019 | -1.5% | -4.4% | +0.8% | |
| Q3 2019 | -6.1% | -4.2% | +19.5% | |
| Q2 2019 | -1.7% | -18.0% | +9.4% | |
| Q1 2019 | +4.9% | +1.3% | +0.2% | |
| Q4 2018 | -8.6% | -3.5% | +10.8% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro